Summary
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy.
Register to download
Meeting Enrollment Goals Breast Cancer
You may also be interested in:
Webcast
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
View Resource
Case Study
PRA Successfully Rescues Phase II Hematology Study
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to…
View Resource
Blog
How Miles, Research, and Hope May Cure Cancer
Read Story
View all related content and resources for Oncology
Explore Insights